Angitia Incorporated Limited

Quick facts

Phase 2 pipeline

• AGA2115 · Oncology
  AGA2115 is a small molecule drug that targets the PI3K/AKT/mTOR pathway.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Angitia Incorporated Limited portfolio CI brief
• Angitia Incorporated Limited pipeline updates RSS